A Maturing Amgen Focuses On Capital Allocation, Late-Stage Pipeline
This article was originally published in The Pink Sheet Daily
Executive Summary
Even as it reaffirms its big long-term bet on R&D, Amgen appeases investors with tweaks to its R&D organization and expansion of its share buyback program.
You may also be interested in...
Amgen Hits Another Emerging Market Target With $700M Turkish Deal
Fulfilling its pledge to dramatically expand internationally, Amgen sealed a deal to purchase coveted drugmaker Mustafa Nevzat, gaining a foothold in Turkey. Meanwhile, its pipeline progresses with no clear winners to help cushion the blows to the company’s ESAs.
In One Day, Change At Biotechs: Leiden To Replace Emmens At Vertex And At Amgen, Bradway Will Become CEO
Board member Jeffrey Leiden, who oversaw the commercialization of Humira at Abbott, will succeed Matthew Emmens as Vertex CEO next February.
BMS Loses Its Top Commercial Executive Anthony Hooper To Amgen In Transition
The head of Bristol-Myers Squibb's operations in the U.S. and beyond, Hooper's departure for Amgen forces Bristol to shift senior management roles.